Table 1.
Patients’ baseline demographic and clinical characteristics (N = 126)
| Characteristic | No. of patients n (%) |
|---|---|
| Median age at IMDC– years (IQR), N = 126 | 55.25–70 (IQR) |
| Male sex | 81 (64.285) |
| White race | 108 (85.714) |
| Median charlson comorbidity index at IMDC, points. (IQR), N = 126 | 7.25–12 (IQR) |
| Cancer type | |
| Melanoma | 29 (23.015) |
| Genitourinary cancer (GU) | 45 (35.714) |
| Lung cancer | 11 (8.730) |
| Others* | 38 (30.158) |
| Cancer stage | |
| Stage III | 16 (12.698) |
| Stage IV | 104 (82.539) |
| Checkpoint inhibitor type | |
| CTLA-4 | 18 (14.285) |
| PD-L1/PD-1 | 49 (38.888) |
| Combination | 57 (45.238) |
| Cancer progression at IMDC | |
| Stable cancer | 39 (30.952) |
| Cancer response | 16 (12.698) |
| Cancer progression | 67 (53.174) |
| Median follow-up duration, mo. (IQR), N = 126 | 13–20 |
| Cancer progression at index IMDC diagnosis N = 126 | |
| Cancer free/remission | 1 (0.793) |
| Stable cancer | 39 (30.052) |
| Cancer response | 16 (12.698) |
| Cancer progression | 67 (53.174) |
| Cancer progression at last follow-up | |
| Cancer free/remission | 11 (8.730) |
| Stable cancer | 33 (26.190) |
| Cancer progression | 78 (61.904) |
| Non-GI organs involving adverse events†– no. (%) | |
| Skin | 6 (0.736) |
| Endocrine | 14 (11.111) |
| Pancreas | 5 (3.968) |
| Liver | 13 (10.317) |
| Musculoskeletal | 4 (3.174) |
| Hematological | 2 (1.587) |
| Lungs | 8 (6.349) |
| Other‡ | 6 (4.761) |
| All-cause mortality: n. % | |
| Disease progression | 58 (82.857) |
| Other reason infection, other irAE, etc.) | 7 (10.447) |
IQR interquartile range, NSAID non-steroidal anti-inflammatory drug, PPI proton pump inhibitor, GI gastrointestinal, GU genitourinary, CTLA-4 cytotoxic T lymphocyte antigen-4, PD-L1/PD-1 programmed death ligand 1/ programmed death-1, IMDC immune-mediated diarrhea and colitis
*Other cancer types included GI/hepatobiliary cancer, head and neck/endocrine cancer, hematologic cancer, breast cancer, cervical cancer, sarcoma cancer
†GI adverse events were defined according-the Common Terminology Criteria for Adverse Events version 5·0.
‡Other non-GI adverse events consisted of mucositis, fatigue, and eye toxicity.